Skip to main content

Adjuvant Endometrial Cancer NRG GY032

Status: Open to Enrollment
Email us to enroll

Study details

View study details on www.clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

Christopher U Jones, M.D., FACR
Christopher U Jones, M.D., FACR
Principal investigator
View profile

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Endometrial Cancer GCT1184-03

    A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

    Status: Open to Enrollment

  • Clinical trial

    Advanced or Recurrent Endometrial Cancer MK2870-033

    A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

    Status: Open to Enrollment

  • Clinical trial

    Neoadjuvant Gynecological Cancers CORT125134-557 BELLA

    An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

    Status: Open to Enrollment

  • Clinical trial

    Advanced Solid Tumors RAINFOL-01

    Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

    Status: Open to Enrollment

  • Clinical trial

    Advanced Cervical Cancer NRG GY037

    A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?